[HTML][HTML] Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
H Pan, R Peto, AMH Restrepo, MP Preziosi… - The Lancet, 2022 - Elsevier
Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …
[HTML][HTML] Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
WHO Solidarity Trial Consortium - Lancet (London, England), 2022 - ncbi.nlm.nih.gov
Background The Solidarity trial among COVID-19 inpatients has previously reported interim
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
H Pan, R Peto, AM Henao-Restrepo, MP Preziosi… - Lancet, 2022 - boris.unibe.ch
BACKGROUND World Health Organization expert groups recommended mortality trials of
four repurposed antiviral drugs-remdesivir, hydroxychloroquine, lopinavir, and interferon …
four repurposed antiviral drugs-remdesivir, hydroxychloroquine, lopinavir, and interferon …
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
WHO Solidarity Trial Consortium - The Lancet, 2022 - scholar.ui.ac.id
Background: The Solidarity trial among COVID-19 inpatients has previously reported interim
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …
[PDF][PDF] Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
L Jančorienė, L Griškevičius - The Lancet, 2022 - epublications.vu.lt
Summary Background The Solidarity trial among COVID-19 inpatients has previously
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …
reported interim mortality analyses for four repurposed antiviral drugs. Lopinavir …
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses
WHO Solidarity Trial … - Lancet (London …, 2022 - pubmed.ncbi.nlm.nih.gov
Background The Solidarity trial among COVID-19 inpatients has previously reported interim
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
Lancet (London, England), 2022 - europepmc.org
Background The Solidarity trial among COVID-19 inpatients has previously reported interim
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …
Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses.
Lancet (London, England), 2022 - europepmc.org
Background The Solidarity trial among COVID-19 inpatients has previously reported interim
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …
mortality analyses for four repurposed antiviral drugs. Lopinavir, hydroxychloroquine, and …